FDA approves exocrine pancreatic insufficiency treatment

ABBOTT PARK, Ill. The Food and Drug Administration has granted an additional approval to a pancreatic enzyme drug made by Abbott, the drug maker said Monday.

The FDA approved Creon (pancrelipase) delayed-release capsules for limited production of pancreatic enzymes due to chronic pancreatitis and removal of the organ. Limited production of pancreatic enzymes prevents proper digestion of food. The drug was already approved in May 2009 for patients with exocrine pancreatic insufficiency due to cystic fibrosis.

“Without proper dosing guidance, some patients have previously attempted to control EPI symptoms by modifying their diets and limiting fat intake,” National Pancreas Foundation executive director Orelle Jackson said in a statement on behalf of Abbott. “However, this approach has yielded limited treatment success.”